TELIX Pharmaceuticals Ltd (TLX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.066x

Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) has a cash flow conversion efficiency ratio of 0.066x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$27.98 Million ≈ $19.80 Million USD) by net assets (AU$421.94 Million ≈ $298.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TELIX Pharmaceuticals Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

TELIX Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how TELIX Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

TELIX Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TELIX Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Sany Heavy Equipment International Holdings Company Limited F:YXS	0.017x
PPB Group Bhd KLSE:4065	0.009x
Bains Mer Monaco PA:BAIN	0.082x
Shift4 Payments Inc NYSE:FOUR	0.075x
Nuvama Wealth NSE:NUVAMA	N/A
Paladin Energy Ltd AU:PDN	-0.003x
Predictive Discovery Ltd AU:PDI	-0.030x
Premium Brands Holdings Corporation TO:PBH	-0.003x

Annual Cash Flow Conversion Efficiency for TELIX Pharmaceuticals Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of TELIX Pharmaceuticals Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see TLX stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$568.21 Million ≈ $402.05 Million	AU$43.03 Million ≈ $30.45 Million	0.076x	-52.79%
2023-12-31	AU$148.91 Million ≈ $105.36 Million	AU$23.88 Million ≈ $16.90 Million	0.160x	+119.29%
2022-12-31	AU$76.92 Million ≈ $54.42 Million	AU$-63.97 Million ≈ $-45.26 Million	-0.832x	+94.89%
2021-12-31	AU$3.64 Million ≈ $2.58 Million	AU$-59.33 Million ≈ $-41.98 Million	-16.290x	-65771.77%
2020-12-31	AU$79.02 Million ≈ $55.91 Million	AU$1.96 Million ≈ $1.39 Million	0.025x	+107.52%
2019-12-31	AU$70.73 Million ≈ $50.05 Million	AU$-23.33 Million ≈ $-16.51 Million	-0.330x	+15.88%
2018-12-31	AU$52.90 Million ≈ $37.43 Million	AU$-20.75 Million ≈ $-14.68 Million	-0.392x	-220.50%
2017-12-31	AU$49.29 Million ≈ $34.88 Million	AU$-6.03 Million ≈ $-4.27 Million	-0.122x	--

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$3.28 Billion

AU$4.64 Billion AUD

Market Cap Rank

#4774 Global

#114 in Australia

Share Price

AU$13.85

Change (1 day)

+0.44%

52-Week Range

AU$8.63 - AU$25.75

All Time High

AU$31.14